Feb. 14, 2022
by Chris De Savi
Biopharma insight
Drug Discovery crystal ball gazing for the year ahead. And the hottest prospects are discussed below. We already have 5 …
Feb. 18, 2022
by Andrii Buvailo
Biopharma insight
The global artificial intelligence (AI) leader Insilico Medicine announced its first milestone in cancer immunotherapy for their external collaboration with …
Oct. 25, 2016
by Andrii Buvailo
Biopharma insight
To date, nature has been the best teacher for drug discovery scientists, especially for those who develop antimicrobial drugs. Lately, …
Dec. 11, 2017
by Alfred Ajami
Biopharma insight
Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is …
Feb. 9, 2020
by Irina Bilous
Biopharma insight
The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some …
May 11, 2022
by Andrii Buvailo
Biopharma insight
Proteins are essential components of living matter – they function as building blocks for cells and tissues, as well as …
Nov. 13, 2017
by Alfred Ajami
Biopharma insight
Consensus seems universal and the news about it flows literally by the minute over gene editing as a future therapy, …
July 29, 2022
by Chris De Savi
Biopharma insight
Lung cancer accounted for 18% of deaths caused by cancer in 2020, making it the leading cause of cancer mortality …
May 25, 2022
by Andrii Buvailo
News
Hong Kong-based clinical stage drug discovery company Insilico Medicine just announced the nomination of a novel preclinical drug candidate for …
May 25, 2022
by Deepti Tayal, Ph.D.
Biopharma insight
Because of endogenous properties, extracellular vesicles (EVs) have shown impressive potential as remedial modalities; nevertheless, more bioengineering refinement is expected …
Aug. 25, 2021
by Liana Relina, Ilia Petrov
Biopharma insight
Gene therapy is still an investigational technique. Viruses are commonly used as vectors to deliver a needed gene to a …
July 28, 2021
by Liana Relina, Illia Petrov
Biopharma insight
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are …